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A B S T R A C T
Adrenal-derived glucocorticoids mediate the physiological response to stress. Chronic disturbances in gluco-
corticoid homeostasis, i.e. in Addison's and Cushing's disease patients, predispose to the development of
atherosclerotic cardiovascular disease. Here we review preclinical and clinical ﬁndings regarding the relation
between changes in plasma glucocorticoid levels and the atherosclerosis extent. It appears that, although the
altered glucocorticoid function can in most cases be restored in the diﬀerent patient groups, current therapies do
not necessarily reverse the associated risk for atherosclerotic cardiovascular disease. In our opinion much at-
tention should therefore be given to the development of a Cushing's disease mouse model that can (1) eﬀectively
replicate the eﬀect of hypercortisolemia on atherosclerosis outcome observed in humans and (2) be used to
investigate, in a preclinical setting, the relative impact on atherosclerosis susceptibility of already available (e.g.
metyrapone) and potentially novel (i.e. SR-BI activity modulators) therapeutic agents that target the adrenal
glucocorticoid output.
1. Glucocorticoids: stress hormones that modulate inﬂammation
and metabolism
Stress is deﬁned as the body's reaction to an external stressor, i.e. an
event that is a real or perceived threat to the human well-being. The
hypothalamus-pituitary-adrenal (HPA)-axis plays an essential role in
the biological response to stress as it initiates a hormone-driven reac-
tion within the body that involves a change in the activity of a variety of
organ systems. Upon exposure to the physiological or psychological
stressor the hypothalamus starts to secrete high levels of corticotropin-
releasing hormone (CRH) (Antoni, 1986; Aguilera, 1994). CRH subse-
quently binds to its receptors in the pituitary resulting in the production
and release of the polypeptide adrenocorticotropic hormone (ACTH)
(Antoni, 1986; Aguilera, 1994). The adrenals respond to the relatively
high levels of ACTH in the blood circulation by stimulating the gen-
eration of the so-called stress hormones, i.e. glucocorticoids such as
cortisol, that initiate the actual physiological response to the stress.
Glucocorticoids belong to the family of steroid hormones that are
produced within the mitochondria from the common precursor cho-
lesterol. The conversion of cholesterol into cortisol encompasses several
steps that are mediated by cytochrome P450 monooxygenases such as
the rate-limiting enzyme cholesterol side-chain cleavage enzyme
(CYP11A1) as well as 3-beta-hydroxysteroid dehydrogenase type 2
(HSD3B2; Fig. 1). The relative importance of each step for the pro-
duction of cortisol is highlighted by the fact that human carriers of
functional mutations in the diﬀerent cytochrome P450 enzymes or
HSD3B2 suﬀer from adrenal insuﬃciency (Wijaya et al., 2019; Perry
et al., 2005; Guran et al., 2016; Speiser, 2001). Adrenals of adult ro-
dents lack the cytochrome P450 enzyme steroid 17alpha-mono-
oxygenase (CYP17A1), also referred to as 17alpha-hydroxylase, 17,20-
lyase, and 17,20-desmolase, with eliminates the possibility to convert
cholesterol into cortisol (Perkins and Payne, 1988; Le Goascogne et al.,
1991; Keeney et al., 1995). As such, as can be appreciated from Fig. 1,
the adrenals from mice and rats produce the glucocorticoid species
corticosterone.
Cortisol and corticosterone execute their biological stress response
through an interaction with the cognate glucocorticoid receptor, the
ﬁrst identiﬁed member of the nuclear receptor superfamily of tran-
scription factors (Hollenberg et al., 1985). The glucocorticoid receptor
is ubiquitously expressed throughout the body with relatively high
expression levels being found in the brain as well as in a variety of
immune cells/tissues (Bookout et al., 2006). Within the brain, the
glucocorticoid receptor mediates the negative feedback control of glu-
cocorticoids on the HPA-axis activity (Reul and de Kloet, 1986; Diorio
et al., 1993; Radley et al., 2006). Activation of the glucocorticoid re-
ceptor in immune cells is generally associated with immune suppression
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as a result of the transrepressive action on its target genes. Functional
antagonism exists between the glucocorticoid receptor and c-Jun, re-
sulting in a decreased activator protein 1 (AP1)-mediated transcrip-
tional activation in immune cells in response to treatment with a glu-
cocorticoid receptor ligand (Schüle et al., 1990). As a result,
glucocorticoids inhibit pro-inﬂammatory interferon signaling in per-
ipheral blood monocytes through a glucocorticoid receptor-mediated
decrease in signal transducer and activator of transcription 1 (STAT1)
production (Hu et al., 2003). Glucocorticoids are also able to suppress
the secretion of the pro-inﬂammatory cytokines tumor necrosis factor-
alpha and interleukin-12 by monocytes/macrophages (Blotta et al.,
1997; Steer et al., 2000; Ma et al., 2004). Furthermore, the viability and
activation state of T cells is reduced through exposure to glucocorti-
coids translating into a reduced production and action of the pro-in-
ﬂammatory cytokine interleukin-2 (Vacca et al., 1990; Kiefer et al.,
1995; Helmberg et al., 1995). Despite the fact that mRNA expression
levels of the glucocorticoid receptor are generally lower in metabolic
tissues than those found in tissues of the immune system, i.e. thymus
and spleen (Bookout et al., 2006), the relatively high levels of gluco-
corticoids found under stress conditions can also signiﬁcantly inﬂuence
metabolism. Expression of the glucocorticoid receptor within the liver
is essential for survival as judged from the observation that mice
lacking functional expression of the glucocorticoid receptor speciﬁcally
only in hepatocytes exhibit severe growth deﬁcits and die shortly after
birth (Tronche et al., 2004). The hepatic glucocorticoid receptor con-
trols transcription of the gluconeogenic enzyme phosphoenolpyruvate
carboxykinase (PEPCK; Imai et al., 1990), which contributes to the
maintenance of blood glucose levels under fasting stress conditions
(Opherk et al., 2004). Their action in adipose tissue also contributes to
the eﬀect of glucocorticoids on blood glucose levels. More speciﬁcally,
glucocorticoid exposure increases the expression of the glucocorticoid
receptor target gene mitogen-activated protein kinase 1, which is
paralleled by diminished insulin-stimulated glucose uptake by adipo-
cytes (Shipp et al., 2010; Tchen et al., 2010). Glucocorticoids also play a
signiﬁcant role in the control of adipocyte triglyceride metabolism as
they, through the action of the glucocorticoid receptor, control the
expression of the key lipolysis genes hormone-sensitive lipase (HSL),
adipocyte triglyceride lipase (ATGL) and monoglyceride lipase (MGL;
Villena et al., 2004; Yu et al., 2010).
2. Changes in the glucocorticoid status are associated with an
increased risk for the development of atherosclerotic
cardiovascular disease in humans
Given that glucocorticoids inﬂuence many diﬀerent physiological
processes it is not surprising that chronic changes in plasma gluco-
corticoid levels underlie the development of certain pathologies. As
mentioned before, a genetic defect in the enzymes involved in the
conversion of cholesterol into cortisol is associated with adrenal in-
suﬃciency. It should be acknowledged that the frequency of mutations
in for instance 21-hydroxylase (21-OH; CYP21A2) is relatively low,
with an incidence of 1/10000–1/20000 newborns (El-Maouche et al.,
2017). As such, adrenal insuﬃciency is considered to be a rare disease.
Subjects carrying a mutation in the CYP21A2 gene generally display
glucocorticoid and/or mineralocorticoid (i.e. aldosterone) deﬁciency
(El-Maouche et al., 2017). This pathology is also known as congenital
adrenal hyperplasia (CAH) since the CYP21A2 deﬁciency is paralleled
by adrenal hyperplasia due to chronically high plasma ACTH levels as a
result of the diminished glucocorticoid-mediated negative feedback on
the HPA-axis. The overall clinical phenotype can vary signiﬁcantly
between individual CAH patients with respect to the disease severity,
since the extent of enzyme function impairment is dependent on the
actual change in the CYP21A2 protein structure/availability. The
classical form of CYP21A2 deﬁciency, i.e. characterized by both glu-
cocorticoid and aldosterone insuﬃciency, commonly presents in in-
fancy as a result of salt-wasting and the development of a life-threa-
tening adrenal crisis rapidly after birth (Speiser et al., 2010). In
contrast, mutations that result in a relatively mild impairment of
CYP21A2 functionality are usually diagnosed during puberty or in
(early) adulthood due to ACTH-induced overproduction of androgens
by the adrenals. Human subjects suﬀering from non-classical CYP21A2
deﬁciency can display precocious pubarche, hirsutism, oligomenor-
rhea/amenorrhea, and female infertility (El-Maouche et al., 2017).
Given that many of the developmental phenotypes found in CAH pa-
tients are secondary to the reduced ability of the adrenals to secrete
glucocorticoids and mineralocorticoids, hormone replacement therapy
serves as the ﬁrst line treatment of subjects suﬀering from CAH.
Evidence is accumulating that adults suﬀering from CAH may also
be at increased risk of developing the metabolic syndrome, a pathology
characterized by at least three of the ﬁve following medical conditions:
central obesity, high blood pressure, high blood glucose levels, high
plasma triglycerides, and low plasma high-density lipoprotein (HDL)-
cholesterol levels. A recent review of literature regarding the relation
between CAH and changes in metabolic status by Improda et al. (2017)
has suggested that children and adolescents with CYP21A2 deﬁciency-
driven CAH are more prone to suﬀer from hypertension and obesity and
display a higher susceptibility for the development of insulin resistance
and possibly type II diabetes (independent of the obesity phenotype).
However, Improda et al. (2017) have concluded based upon the re-
viewed studies that the presence of CAH does not impact signiﬁcantly
on the plasma lipid proﬁle. All 5 abovementioned conditions associated
with the metabolic syndrome individually increase the risk for the de-
velopment of cardiovascular disease, with the combination translating
into a ~2-fold higher chance of suﬀering from a myocardial infarction
or stroke (Ninomiya et al., 2004).
Atherosclerosis, narrowing of the vessel lumen due to accumulation
of cholesterol and other lipoid substances in so-called macrophage foam
cells within the vessel wall, represents the primary underlying cause of
Fig. 1. Schematic representation of the steps involved in the conversion of
cholesterol into the main circulating glucocorticoid species cortisol (non-
rodents) and corticosterone (rodents). CYP11A1, side-chain cleavage en-
zyme. HSD3B2, 3-beta-hydroxysteroid dehydrogenase type 2. CYP21A2, 21-
hydroxylase. CYP11B1, 11-beta-hydroxylase. CYP17A1, steroid 17alpha-
monooxygenase.
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cardiovascular disease (Ross, 1986; Ross and Glomset, 1976a and
1976b). As such, lipid-lowering statin treatment constitutes the ﬁrst
line therapy for subjects considered at high risk of developing cardio-
vascular disease. Although arterial lipid deposition in macrophage foam
cells is a hallmark of the development of atherosclerotic lesions, it
should be acknowledged that the pathogenesis of atherosclerosis is also
characterized by endothelial cell dysfunction, leukocyte inﬁltration,
cytokine-driven inﬂammation, and smooth muscle cell migration and
proliferation (Fig. 2) (Ross, 1986; Ross and Glomset, 1976a/b). The
relative importance of the inﬂammatory component in atherosclerotic
cardiovascular disease has become apparent in the recent CANTOS trial
which showed a beneﬁcial impact of pro-inﬂammatory cytokine inter-
leukin-1beta (IL-1beta) inhibition on cardiovascular disease outcome
that was independent of cholesterol lowering (Ridker et al., 2017).
In accordance with the general assumption that presence of the
metabolic syndrome increases the risk of atherosclerotic cardiovascular
disease, the relatively high metabolic syndrome predisposition of CAH
patients is associated with a concomitantly higher susceptibility for the
development of atherosclerosis. More speciﬁcally, Amr et al. (2014),
Akyürek et al. (2015), and Metwalley et al. (2016) observed that chil-
dren suﬀering from CAH exhibited a higher atherosclerosis extent as
compared to age-matched unaﬀected human control subjects, as judged
by their higher carotid intima-media thickness. In support, Sartorato
et al. (2007) have also detected a relatively higher intima-media
thickness in CAH patients compared to healthy controls in adulthood. A
meta-analysis of 12 longitudinal and two cross-sectional studies that
included data from 437 CAH patients, covering both children and adult
populations, revealed that the intima thickness is on average 0.08 mm
larger in patients than in healthy individuals without CAH (Tamhane
et al., 2018).
The higher cardiovascular disease susceptibility does not appear to
be restricted to CAH patients, but rather appears a common ﬁnding in
subjects suﬀering from (primary) adrenal insuﬃciency. A study by
Bergthorsdottir et al. (2006) indicated that the relative risk score for all-
cause mortality is > 2-fold higher in Addison's disease patients with
primary adrenal insuﬃciency, which can be primarily related to a
signiﬁcant increase in cardiovascular disease susceptibility. Skov et al.
(2019) also observed that cardiovascular disease risk was higher in
Addison's disease patients as compared to healthy controls. An inter-
esting point that can be derived from the data of Skov et al. (2019) is
that the cardiovascular predisposition associated with Addison's disease
may be much higher in female than in male patients. However, the
underlying reason for this apparent gender bias remains to be un-
covered. Notably, the negative eﬀect on overall cardiovascular disease
risk appears to be driven by an eﬀect on ischemic heart disease and
cannot be attributed to a rise in the risk for the development of cere-
brovascular disease (Skov et al., 2019).
Improda et al. (2017) have implied that high extent hormone re-
placement contributes signiﬁcantly to the metabolic disturbances, in-
crease in blood pressure and the associated cardiovascular disease risk
found in CAH patients. In agreement, a positive relationship was de-
tected between the hydrocortisone and ﬂudrocortisone dose used and
cardiovascular disease risk in the cohort studied by Skov et al. (2019),
with intake of the highest doses of both hydrocortisone and ﬂu-
drocortisone translating into a ≥2-fold increase in the odds ratio for
cardiovascular disease in both men and women. It should be noted that
the hormone treatment-associated change in the metabolic status alone
does, however, not fully explain the overall increased mortality rate of
human subjects suﬀering from CAH and Addison's disease, since
Chantzichristos et al. (2017) observed that primary adrenal in-
suﬃciency even further reduces the life expectancy also in an all dia-
betic population.
The notion that relatively high plasma glucocorticoid levels are a
direct cause of metabolic complications and cardiovascular disease is
supported by ﬁndings from human subjects suﬀering from Cushing's
syndrome. Cushing's syndrome is a rare, chronic disease characterized
Fig. 2. Overview of key processes involved in the initial development and progression of atherosclerotic lesions. A combination of relatively high plasma
LDL-cholesterol concentrations and other cardiovascular disease risk factors such as smoking induce damage to the endothelium which results in monocyte in-
ﬁltration into the vessel well. Monocytes are locally converted into macrophages that can engulf LDL particles to become foam cells which leads to fatty streak lesion
formation. In response to the chronic inﬂammation, e.g. cytokine secretion by attracted lymphocytes, smooth muscle cells migrate, proliferate and change phenotype
to produce collagen, which enables the formation of a ﬁbrous cap covering the more advanced plaque.
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by endogenous or exogenous hypercortisolemia. Cushing's disease, i.e.
the presence of an ACTH-secreting tumor in the pituitary which over-
rules the glucocorticoid-mediated feedback on the HPA-axis, represents
the primary underlying cause of the hypercortisolemia (70% of all
Cushing's cases; Nieman et al., 2015; Pivonello et al., 2017). Early signs
of the presence of Cushing's syndrome include easy bruising, facial
plethora, proximal myopathy (or proximal muscle weakness), and the
development of striae (Nieman et al., 2008). In children, Cushing's
syndrome can also be apparent from excessive weight gain (obesity) in
the context of decreasing growth velocity (Nieman et al., 2008).
However, the prevalence of hypertension, glucose intolerance, and
diabetes is also generally higher in Cushing's syndrome patients than in
non-diseased human subjects (Nieman et al., 2008; Feelders et al.,
2012; Pivonello et al., 2017). Plotz et al. already in 1952 observed that
the highest mortality amongst Cushing's syndrome patients is due to
either infections or cardiovascular diseases, i.e. cardiac failure. In ac-
cordance, a 5 times higher vascular disease mortality rate was detected
by Etxabe and Vazquez (1994) in subjects aﬀected by Cushing's disease.
About similar increases in the relative risk for the development of a
myocardial infarction or stroke were described by Lindholm et al.
(2001) and Dekkers et al. (2013) after intensively following the clinical
course of two independent cohorts of Cushing's syndrome patients.
Clayton et al. (2011) even found a 13 times higher mortality rate re-
lated to vascular complications in Cushing's patients. A meta-analysis
by Clayton et al. (2011) on the outcomes of 4 diﬀerent studies in-
vestigating the impact of Cushing's syndrome on overall mortality has
indicated that cardiovascular disease-related mortality rates are ~5.5-
fold higher in Cushing's syndrome patients than in the general popu-
lation. Studies by Dalmazi et al. in a cohort of human subjects with
incidental adrenal tumors have suggested that even a minor, chronic
increase in plasma cortisol levels translated into an increased risk of
cardiovascular events and mortality (Di Dalmazi et al., 2014). The in-
crease in overall cardiovascular disease (mortality) risk in Cushing's
syndrome patients is probably secondary to an increased atherosclerotic
plaque burden, given that a meta-analysis by Lupoli et al. (2017) has
indicated that both the carotid intima-media thickness and the in-
cidence of carotid plaques are signiﬁcantly higher in subjects suﬀering
from Cushing's than in healthy controls. In line with the overall con-
clusion that chronic glucocorticoid overexposure predisposes humans
to atherosclerotic cardiovascular disease, stress has also been shown to
aggravate cardiovascular disease burden. A 27 year follow-up of
136.673 Swedish individuals showed that the cardiovascular disease
incidence was 1.64 higher in subjects that were diagnosed for a stress-
related condition as compared to non-stressed control subjects (Song
et al., 2019). In addition, patients with stable coronary artery disease
that persistently experience moderate or greater psychological stress
display an almost 4-fold increase in cardiovascular mortality risk
(Stewart et al., 2017).
3. Glucocorticoids elicit variable eﬀects on atherosclerosis burden
in preclinical animal models
The ﬁrst animal studies regarding the ability of glucocorticoids to
modulate atherosclerosis susceptibility were executed in rabbits in the
1960s, because rabbits rapidly develop atherosclerotic lesions within
the thoracic aorta in response to feeding them a diet enriched in cho-
lesterol. In contrast to what would be expected from the atherosclerosis
stimulating eﬀect of Cushing's syndrome in humans, Bailey and Butler
showed that high dose oral administration of a variety of glucocorticoid
species, i.e. dexamethasone, 9-alpha-ﬂuorohydrocortisone/ﬂu-
drocortisone, and methylprednisolone, signiﬁcantly reduces plaque
load in high cholesterol diet-fed New Zealand White rabbits (Bailey and
Butler, 1973). The positive eﬀect of glucocorticoid treatment on
atherosclerosis outcome was suggested to be primarily related to the
anti-inﬂammatory actions of the respective glucocorticoid species, since
non-steroidal anti-inﬂammatory drugs were also capable of reducing
atherosclerosis susceptibility in a similar experimental setting (Bailey
and Butler, 1973). Asai et al. (1993) and Naito et al. (1992) observed
that dexamethasone was also able to execute its atherosclerosis-redu-
cing eﬀect in New Zealand White rabbits when administered through
intra-muscular injection. The decrease in atherosclerosis burden in
dexamethasone-treated rabbits in the study by Asai et al. (1993) coin-
cided with a reduction in the lesional macrophage and lymphocyte
content. Notably, ﬁndings from Hagihara et al. (1991) have shown that
dexamethasone treatment markedly lowers the adhesion of leukocytes
to the aortic endothelium, which also explains the dexamethasone-in-
duced protection to cuﬀ-induced intimal thickening observed in Japa-
nese white rabbits. Anti-inﬂammatory glucocorticoid administration to
rabbits, i.e. oral prednisone treatment, similarly reduces the restenosis
extent in response to stent implantation into atherosclerosis-containing
iliac arteries (Ribichini et al., 2007). In accordance with the notion that
potent anti-inﬂammatory actions drive the glucocorticoid-mediated
atheroprotection, the positive eﬀect on balloon injury-induced rest-
enosis upon dexamethasone treatment appears to be related to a re-
duced monocyte chemoattractant protein-1 (MCP-1)-mediated attrac-
tion of lymphocytes towards the injured vessel wall (Poon et al., 2001).
Data from Cavallero et al. (1976) have highlighted that the gluco-
corticoid-induced reduction in atherosclerosis susceptibility in rabbits
is possibly due to local actions on cells within the atherosclerotic
plaque, i.e. through a reduction in the proliferation rate of smooth
muscle cells and/or inﬁltrated immune cells. In support, liposome-
mediated local delivery of a single glucocorticoid dose to macrophages
into atherosclerotic plaques results in a diminished lesion inﬂammatory
status, as judged by the observed reduction in aortic 18F-ﬂuoro-deoxy-
glucose uptake in prednisolone phosphate liposome-administered New
Zealand White rabbits (Lobatto et al., 2010). Hypercholesterolemia is a
determinant factor in the development of atherosclerotic lesions in New
Zealand White rabbits based upon the observation that plasma cho-
lesterol levels correlate signiﬁcantly to total lesion area and the lesional
cholesterol contents (Shaish et al., 1997). Findings from Tvedegaard
et al. (1983) have suggested that, apart from the anti-atherogenic anti-
inﬂammatory eﬀect, glucocorticoid treatment inhibits the formation of
atherosclerotic lesions through reducing the aortic uptake of cholesterol
from the plasma compartment. As such, no increased atherosclerosis
burden was measured in their methylprednisone-treated rabbits despite
the signiﬁcant increase in the plasma hyperlipidemia extent after high
dose methylprednisone treatment (Tvedegaard et al., 1983).
Wild-type mice are resistant to the development of atherosclerotic
lesions, as their plasma levels of pro-atherogenic, cholesterol-rich low-
density lipoproteins (LDL) remain too low to initiate the atherogenesis
process even after high cholesterol diet feeding (Ishibashi et al., 1994).
However, in the earlier 90's, two diﬀerent lines of genetically modiﬁed
mice were generated that exhibit a high susceptibility for the devel-
opment of atherosclerotic lesions. The group of Dr. Nobuyo Maeda have
developed a strain of apolipoprotein E (APOE) knockout mice that
display spontaneous arterial lesions, since the genetic lack of APOE
protein is associated with the accumulation of cholesterol-rich very-
low-density lipoprotein (VLDL) and chylomicron remnants in the blood
compartment (Zhang et al., 1992). In contrast, mice with a genetic
deﬁciency of the LDL receptor (LDLR), generated by Dr. Joachim Herz
and colleagues (Ishibashi et al., 1993), only display mild hypercholes-
terolemia upon regular chow diet feeding with a comparable lipopro-
tein proﬁle as normally found in humans. LDLR knockout mice there-
fore require dietary cholesterol supplementation to facilitate the
development of atherosclerotic lesions (Ishibashi et al., 1993). With the
introduction of these new animal models for human cardiovascular
disease, a concomitant shift from rabbits to mice occurred in the choice
of the species used for (in vivo) studies regarding the role of gluco-
corticoids in the atherosclerosis pathology. Stein et al. (1998) showed
that glucocorticoid treatment of mice was associated with a diminished
ﬂux of cholesterol back to the liver for subsequent excretion into the
bile (reverse cholesterol transport), which translated into a prolonged
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accumulation of LDL-cholesterol in the injection compartment. This
initial ﬁnding in mice suggested that mice as compared to rabbits would
probably serve as better model to investigate the eﬀect of glucocorti-
coids on human atherosclerosis disease. Within cells targeted by glu-
cocorticoids, i.e. hepatocytes and macrophages, the enzyme 11beta-
hydroxysteroid dehydrogenase type 1 (HSD11B1) can convert inactive
cortisone into active cortisol, thereby raising the eﬀective cellular
glucocorticoid tone. This action is counterbalanced by the enzyme
HSD11B2 that inactivates cortisol through converting it back to corti-
sone. Hermanowski-Vosatka et al. (2005) observed that pharmacolo-
gical inhibition of the HSD11B1 activity was associated with a dimin-
ished atherosclerotic lesion growth in APOE knockout mice, fueling the
suggestion that glucocorticoids should be considered pro-atherogenic.
Treatment with HSD11B1 inhibitors or a genetic deletion of HSD11B1
protein function similarly reduced the extent or aortic cholesterol ac-
cumulation in Western-type diet-fed APOE knockout mice (Luo et al.,
2013; García et al., 2013) and severely obese Ay/a LDLR knockout mice
(Nuotio-Antar et al., 2007). It has been suggested that the athero-
sclerosis reducing eﬀect of HSD11B1 deﬁciency can for the large part be
attributed to a beneﬁcial impact on lesional macrophage cholesterol
handling (Kipari et al., 2013; García et al., 2013). In this context it is
interesting to note that van der Valk et al. (2016) have shown that
liposome-mediated local delivery of prednisolone to plaque macro-
phages is associated with accelerated atherosclerosis in LDLR knockout
mice, as expected. In accordance with a pro-atherogenic role for glu-
cocorticoids, Schepers et al. (2006) detected a> 2-fold rise in plasma
cholesterol levels and a concomitant 4.7-fold increase in the athero-
sclerotic plaque area in the aortic root of dexamethasone-treated ge-
netically modiﬁed hyperlipidemic APOE3Leiden mice. In striking con-
trast to the notion that (excess) glucocorticoids execute a pro-
atherogenic eﬀect in mice, high dose dexamethasone treatment reduced
the arterial cholesterol load in wild-type mice fed a cholesterol and
cholic acid-enriched atherogenic diet despite the fact that glucocorti-
coid exposure was associated with exacerbated hypercholesterolemia
(Tauchi et al., 2001). Studies by Auvinen et al. (2013) in APOE3Leiden
mice also carrying the human cholesteryl ester transfer protein (CETP)
transgene have shown a similar atheroprotective eﬀect of both transient
and continuous glucocorticoid excess. Furthermore, APOE knockout
mice lacking the glucocorticoid receptor in their endothelial cells de-
veloped more severe atherosclerotic lesions in the aorta, the brachio-
cephalic artery, as well as in the aortic sinus (Goodwin et al., 2015). In
support of a highly variable eﬀect of glucocorticoids on atherosclerosis
outcome, HSD11B1 inhibitor treatment did not modulate athero-
sclerosis susceptibility in Western-type diet fed LDLR knockout mice
(Nuotio-Antar et al., 2007). In addition, HSD11B1 inhibition did not
reduce the aortic plaque load in chow diet-fed leptin deﬁcient APOB100
transgenic obese LDLR knockout mice (Lloyd et al., 2009). A selective
disruption of glucocorticoid receptor functioning in macrophages in
LDLR knockout mice (Preusch et al., 2008) or treatment of high fat diet-
fed APOE knockout mice with dexamethasone (Zhang et al., 2015) did
also not translate into an altered atherosclerosis susceptibility. As re-
cently observed by our group, the cholestasis-associated hypercorti-
costeronemia also fails to impact atherosclerosis extent in APOE
knockout mice (van der Geest et al., 2019). Furthermore, we have
previously noted that a complete loss of adrenal glucocorticoid pro-
duction as a result of bilateral adrenalectomy is not associated with an
eﬀect on atherosclerosis susceptibility in APOE knockout mice
(Hoekstra et al., 2013c), while it actually increases the susceptibility to
the development of atherosclerotic lesions in LDLR knockout mice fed a
pro-inﬂammatory cholic acid-containing Western-type diet (van der
Sluis et al., 2012). These combined ﬁndings indicate that (1) the eﬀect
of (endogenous) glucocorticoids on disease outcome in atherosclerosis
mouse models is very variable and (2) it is worthwhile to put eﬀort in
the generation of predictive Cushing's syndrome-related atherosclerosis
mouse models.
Zebraﬁsh have emerged as a low-cost, non-mammalian preclinical
model system that can perhaps also be used to study the interaction
between glucocorticoids and atherosclerotic cardiovascular disease.
Glucocorticoid functionality in zebraﬁsh mimics that of humans at
several important levels, as reviewed by Schaaf et al. (2009). For in-
stance, as opposed to mice, adrenals from zebraﬁsh express a functional
CYP17 protein and are therefore able to produce cortisol (Wang and Ge,
2004). Furthermore, zebraﬁsh ubiquitously express both the alpha and
beta isoforms of the glucocorticoid receptor, with the alpha subtype
exhibiting the highest relative tissue expression levels (Schaaf et al.,
2008). An interesting aspect from applying zebraﬁsh as potential
atherosclerosis animal model is that disease progression can theoreti-
cally be followed in living animals, i.e. through in vivo imaging of
ﬂuorescently-labeled macrophages, given that zebraﬁsh bodies are
optically transparent. Feeding a diet enriched in cholesterol eﬀectively
induces hypercholesterolemia in zebraﬁsh (Schlegel, 2016). The Miller
group was the ﬁrst to suggest that this hypercholesterolemia also
translates into the deposition of lipids within the arterial vessel wall
(Stoletov et al., 2009). However, in spite of multiple attempts, we have
not been able to verify that the cholesterol enriched diet-induced hy-
percholesterolemia is indeed able to stimulate the formation of foam
cell-rich lesions in zebraﬁsh (unpublished data Verwilligen et al.). We
therefore consider the qualiﬁcation of zebraﬁsh as established athero-
sclerosis animal model controversial. In this context, it is also important
to acknowledge that recent experimental evidence from Luo et al.
(2019) suggests that other myeloid cells (i.e. neutrophils) than macro-
phages - typically present in human atherosclerotic lesions - accumulate
in the vessel wall of hypercholesterolemic zebraﬁsh. More detailed re-
search into this speciﬁc topic is clearly warranted.
4. Impact of current treatments for hypercortisolemia on
(atherosclerotic) cardiovascular disease risk
Although the underlying disease mechanism can be quite diﬀerent
between individual Cushing's syndrome patients that suﬀer from hy-
percortisolemia, most disease cases can be treated or cured (Nieman
et al., 2015). Treatment regimens with exogenous glucocorticoids as
part of for instance anti-inﬂammatory rheumatoid arthritis therapies
can be stopped or adapted to reverse the Cushing's syndrome-associated
symptoms, whilst ACTH-producing pituitary tumors are treated through
a combination of surgery, chemotherapy, and/or radiation (Nieman
et al., 2015). Furthermore, Cushing's syndrome patients are prescribed
steroidogenesis blockers such as the 11-beta-hydroxylase (CYP11B1)
inhibitor metyrapone or glucocorticoid receptor antagonists, i.e. RU-
486 (mifepristone) to respectively reduce the adrenal glucocorticoid
output or diminish the metabolic eﬀects associated with relatively high
plasma cortisol levels (nicely reviewed by Cuevas-Ramos and Fleseriu,
2014). A retrospective multi-center study published in 2015 has shown
that metyrapone treatment is an eﬀective therapy for short- and long-
term control of hypercortisolemia in Cushing's syndrome with>50%
of the patients reaching the (normalized) cortisol target of less than
300 nM/10.9 μg/dl (Daniel et al., 2015). However, it should be ac-
knowledged that several side eﬀects related to metyrapone treatment
(acne, hirsutism, lethargy, dizziness, ataxia, nausea, hypertensive crisis,
hypokalemia, edema, and adrenal insuﬃciency) contribute to a limited
availability or use of metyrapone in most countries (Cuevas-Ramos and
Fleseriu, 2014). Interestingly, despite eﬀective treatment of the hy-
percortisolemia, the increased cardiovascular risk is not reversed in
Cushing's syndrome patients after 1 year or 5 years of remission
(Faggiano et al., 2003; Colao et al., 1999; Webb and Valassi, 2018). This
appears to be related to the fact that metabolic complications associated
with active Cushing's syndrome such as relatively high blood pressure,
altered plasma lipid levels and obesity are not fully resolved through
current cortisol lowering treatments (Faggiano et al., 2003; Colao et al.,
1999; Barahona et al., 2009; Webb and Valassi, 2018). Glucocorticoid
secretion by the adrenals normally follows an ultradian rhythm
(Stavreva et al., 2009). Importantly, preclinical studies by
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Sarabdjitsingh et al. (2010) have observed a signiﬁcant ﬂattening of the
plasma glucocorticoid rhythmicity upon chronic glucocorticoid re-
ceptor overactivation in rats. It is therefore highly likely that ineﬀective
restoration of plasma glucocorticoid rhythmicity also partially under-
lies the inability of the indicated treatments to completely reverse all
complications related to the hypercortisolemia. Pro-thrombotic and
pro-inﬂammatory factors that can inﬂuence the overall atherosclerotic
cardiovascular disease risk also remain signiﬁcantly higher in the cir-
culation during Cushing's syndrome remission (Aranda et al., 2018;
Barahona et al., 2009; Webb and Valassi, 2018). From large-scale
clinical trials is has become evident that both lipid lowering treatments,
i.e. statins, as well as anti-inﬂammatory approaches can serve as
therapy for subjects at risk of developing atherosclerotic cardiovascular
disease (Boekholdt et al., 2014; Ridker et al., 2017). It will be inter-
esting to validate whether any of these approaches is able to eliminate
the residual cardiovascular risk in Cushing's syndrome patients in re-
mission. However, in light of the limited number of new Cushing's
syndrome cases identiﬁed annually (incidence: 3.2 cases per one mil-
lion inhabitants (Wengander et al., 2019), it may be diﬃcult or even
impossible to compile a cohort of patients that is suﬃciently large to
provide an answer to this question.
5. Adrenal cholesterol acquisition by scavenger receptor BI (SR-
BI): a novel therapeutic target in treatment of Cushing's
syndrome?
Cortisol synthesis intermediates such as 11-dexoycortisol can be
converted into androgen precursors, leading to oﬀ-target eﬀects related
to androgen excess upon chronic treatment of Cushing's syndrome pa-
tients with standard steroidogenesis inhibiting drugs, i.e. metyrapone
(Cuevas-Ramos and Fleseriu, 2014). Modulation of the adrenal cho-
lesterol substrate availability could theoretically serve as an alternative
to inhibiting individual steps in the conversion of cholesterol into cor-
tisol to overcome hypercortisolemia. It has become evident from studies
in both mice and humans that the adrenal cholesterol pool used for the
synthesis of glucocorticoids is derived from either the novo cholesterol
synthesis within the adrenals or via SR-BI- or LDLR-mediated uptake of
cholesterol from circulating lipoproteins, with the latter being the pri-
mary acquisition route (Fig. 3). Studies in rats have shown that the
basal activity of the rate-limiting enzyme in de novo cholesterol
synthesis, HMG-CoA reductase (HMGCR), within the adrenals is low
(Balasubramaniam et al., 1977). In further support, little to no adrenal
activity of HMGCR has been found in normolipidemic wild-type mice
(Plump et al., 1996). As such, pharmacological inhibition of the
HMGCR activity through statin treatment does not impact plasma
cortisol levels in (hypercholesterolemic) humans (Illingworth and
Corbin, 1985; Laue et al., 1987; Fojo et al., 1987; Mol et al., 1989; Ide
et al., 1990; Takeda et al., 1991; Azzarito et al., 1992). HMGCR ex-
pression and activity levels are markedly increased in the adrenals of
mice in response to the absence of cholesterol-containing lipoproteins
(Plump et al., 1996; Hoekstra et al., 2010), suggesting that de novo
synthesis can make a signiﬁcant contribution to adrenal steroidogen-
esis. In agreement, simvastatin treatment further reduces the already
lowered adrenal glucocorticoid output in hypocholesterolemic APOA1
knockout mice (Ouweneel et al., 2017). Based upon the combined ob-
servations that cholesterol ester stores within the adrenals from HDL
deﬁcient APOA1 knockout mice are almost fully deprived and that
these mice suﬀer from relative glucocorticoid insuﬃciency (Plump
et al., 1996), it was long hypothesized that HDL should be regard as the
primary source of the steroidogenic cholesterol pool. This suggestion
was supported by the ﬁnding that adrenal cholesterol stores and the
overall adrenal glucocorticoid function are similarly reduced in le-
cithin–cholesterol acyltransferase (LCAT) knockout mice, which are
unable to convert pre-beta HDL particles into cholesterol ester-enriched
mature HDL particles, as well as in human subjects carrying a func-
tional mutation in the LCAT gene (Hoekstra et al., 2013b; Bochem et al.,
2013). In contrast, follow-up studies in chow diet-fed LDLR knockout
mice that exhibit a human-like lipoprotein proﬁle have shown that HDL
is actually redundant for adrenal steroidogenesis (Hoekstra and Van
Eck, 2016). It can thus be anticipated that, in humans, non-HDL lipo-
proteins such as the APOB-containing lipoproteins VLDL and LDL are of
quantitative importance as adrenal cholesterol donors. This hypothesis
ﬁts with clinical data from Illingworth et al. that ACTH-stimulated
cortisol secretion is lower in abetalipoproteinemic (LDL deﬁcient) pa-
tients as compared to unaﬀected controls (Illingworth et al., 1980,
1982a; 1982b). Given that hypercholesterolemic APOE knockout mice
display hypercorticosteronemia (Raber et al., 2000), an eﬀect that is not
driven by elimination of adrenocortical APOE production (van der Sluis
et al., 2019), mechanistic studies in total body APOE knockout mice can
possibly shed more light on the importance of APOB-containing lipo-
proteins in the context of adrenal steroidogenesis.
SR-BI is predominantly known for its role in HDL metabolism. The
selective uptake of cholesterol esters from HDL particles by the liver
and adrenals is impaired in SR-BI knockout mice (Out et al., 2004a;
Brodeur et al., 2005). As a result of the accumulation of cholesterol
ester-enriched large HDL particles in the circulation, plasma HDL-cho-
lesterol levels are signiﬁcantly higher in SR-BI knockout mice as com-
pared to wild-type littermates (Rigotti et al., 1997). Human carriers of a
functional mutation in the SR-BI gene are also characterized by ele-
vated plasma HDL-cholesterol levels (Vergeer et al., 2011; Zanoni et al.,
2016; Helgadottir et al., 2018). However, SR-BI is also able to facilitate
the cellular delivery of cholesterol from non-HDL APOB-containing li-
poprotein species such a chylomicrons (Out et al., 2004b), VLDL (Van
Eck et al., 2008) and LDL (Swarnakar et al., 1999; Stangl et al., 1999;
Brodeur et al., 2005). In this context, it is of interest to note that a large
body of evidence has indicated that - next to hypocholesterolemia - a
disruption in the functionality of the scavenger receptor BI can also
underlie an impaired glucocorticoid response in mice and humans.
More speciﬁcally, total body SR-BI knockout mice fail to increase their
plasma corticosterone concentrations in response to a LPS stress trigger
to such a level that they can overcome the development of septic shock
(Cai et al., 2008; Hoekstra et al., 2009). As a result, a markedly higher
lethality rate is observed in SR-BI knockout mice than in control mice
upon high dose LPS exposure (Cai et al., 2008). A signiﬁcantly dimin-
ished rise in plasma corticosterone levels is also detected in total body
and adrenal-speciﬁc SR-BI knockout mice as compared to their wild-
type controls upon exposing them to fasting stress (overnight food de-
privation) (Hoekstra et al., 2008, 2009, 2013a). The adrenal ster-
oidogenesis capacity is also signiﬁcantly attenuated in human subjects
carrying the P297S functional mutation in the SR-BI gene, as judged by
the ﬁnding that the urinary excretion of sterol metabolites and cortisol
response to ACTH stimulation is reduced in P297S mutation carriers as
compared to unaﬀected human controls (Vergeer et al., 2011). Notably,
human SRBI P297S mutation carriers frequently show clinical signs
related to adrenal insuﬃciency (Vergeer et al., 2011). Given that
baseline plasma glucocorticoid levels are not reduced as a result of SR-
BI deﬁciency (Hoekstra et al., 2008, 2009; 2013a; Vergeer et al., 2011),
it can be anticipated that adrenocortical cell SR-BI plays an essential
role speciﬁcally in the ACTH-mediated glucocorticoid response in mice
and humans. Since the majority of clinical Cushing's cases are resulting
from ACTH-mediated adrenal overstimulation, i.e. ACTH-producing
pituitary tumors, it can be suggested that targeting SR-BI functionality
may be of use in the treatment of Cushing's syndrome patients. Im-
portantly, SR-BI contributes to the cellular entry of hepatitis C virus
(Westhaus et al., 2017; Gao et al., 2017) and SR-BI blocking agents, i.e.
the antagonist ITX5061, are therefore currently being developed as
anti-hepatitis C drugs (Syder et al., 2011; Rowe et al., 2016). Since
ITX5061 has been shown to be well tolerated with measurable plasma
concentrations during short-term therapy in patients with hepatitis C
virus infection undergoing liver transplantation (Rowe et al., 2016), we
consider it clearly of interest to evaluate the eﬀect of ITX5061 treat-
ment on the adrenal steroid function in both healthy human subjects as
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well as in Cushing's syndrome patients. These proposed studies will not
only highlight the potential of SR-BI blocking agents as novel therapy
for the treatment of Cushing's disease, but also increase our under-
standing of SR-BI's role in adrenal glucocorticoid homeostasis in hu-
mans.
6. Concluding remarks
It has become evident that glucocorticoids are essential players in
the physiological response to stress based upon their ability to modulate
both inﬂammatory and metabolic processes. As a result, disturbances in
plasma cortisol levels predispose to the development of a variety of
pathologies with atherosclerotic cardiovascular disease being a top
killer in patients suﬀering from primary adrenal insuﬃciency or
Cushing's syndrome/disease. Although the altered glucocorticoid
function can in most cases be restored in these diﬀerent patient groups,
i.e. through hormone replacement or steroidogenesis inhibitor treat-
ment, respectively, it should be acknowledged that current therapies do
not necessarily reverse the associated susceptibility to cardiovascular
disease. In our opinion much attention should therefore be given to the
development of a Cushing's disease mouse model that can (1) eﬀec-
tively replicate the eﬀect of hypercortisolemia on atherosclerosis out-
come observed in humans and (2) be used to investigate, in a preclinical
setting, the relative impact on atherosclerosis susceptibility of already
available (e.g. metyrapone) and potentially novel (i.e. SR-BI activity
modulators) therapeutic agents that target the adrenal glucocorticoid
output.
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